Ketorolac (Toradol) Dosing, Contraindications, and Monitoring
For adult patients with acute pain, ketorolac should be dosed at 15-30 mg IV/IM every 6 hours (maximum 120 mg/day) or 10-20 mg orally every 4-6 hours (maximum 40 mg/day), with total treatment duration not exceeding 5 days across all routes of administration. 1
Dosing Recommendations
Parenteral Administration
- Standard adult dose (age 17-64, weight ≥50 kg): 60 mg IM as initial dose, then 15-30 mg every 6 hours 2
- Reduced dose (age ≥65, weight <50 kg, or renal impairment): Lower initial and maintenance doses required 3
- Maximum daily dose: 120 mg 2
- Maximum treatment duration: 5 days total (IV/IM plus oral combined) 1
Oral Administration
Oral ketorolac is only indicated as continuation therapy following IV/IM dosing 1:
- Age 17-64: 20 mg once, then 10 mg every 4-6 hours as needed (maximum 40 mg/day) 1
- Age ≥65, renal impairment, or weight <50 kg: 10 mg once, then 10 mg every 4-6 hours as needed (maximum 40 mg/day) 1
Recent evidence demonstrates that lower doses (10-20 mg) provide equivalent analgesia to higher doses (≥30 mg) with potentially fewer adverse effects 4, 5. The analgesic effect of ketorolac exhibits a ceiling effect, meaning doses above 30 mg do not provide additional pain relief 4.
Absolute Contraindications
Do not use ketorolac in patients with: 1, 6, 7
- Active or history of peptic ulcer disease or GI bleeding
- Advanced renal impairment or risk of renal failure
- Aspirin/NSAID-induced asthma or hypersensitivity
- Cerebrovascular hemorrhage or bleeding disorders
- Pregnancy, labor, delivery, or nursing
- Concurrent use with other NSAIDs or anticoagulants (warfarin, heparin)
- Pheochromocytoma
- Seizure disorder
High-Risk Populations Requiring Caution
Renal Toxicity Risk 3
- Age ≥60 years
- Compromised fluid status
- Concurrent nephrotoxic drugs (cyclosporine, cisplatin)
- Action: Discontinue if BUN/creatinine doubles or hypertension develops/worsens
GI Toxicity Risk 3
- Age ≥60 years
- History of peptic ulcer disease
- Significant alcohol use (≥2 drinks/day)
- Hepatic dysfunction
- Action: Discontinue if peptic ulcer or GI hemorrhage develops; consider COX-2 inhibitor or gastroprotection
Cardiac Toxicity Risk 3
- History of cardiovascular disease
- Concurrent anticoagulation
- Action: Discontinue if hypertension develops/worsens
Bleeding Risk 1
The risk of clinically serious GI bleeding is dose-dependent and age-dependent:
- Age <65 with ≤60 mg/day: 0.4% risk
- Age ≥65 with >120 mg/day: 7.7% risk
- With history of GI bleeding, age ≥65, >120 mg/day: 25% risk
Monitoring Requirements
Baseline Assessment 3
- Blood pressure
- BUN and creatinine
- Liver function tests (alkaline phosphatase, LDH, AST, ALT)
- Complete blood count
- Fecal occult blood
Follow-up Monitoring 3
- Repeat every 3 months if chronic use (though ketorolac should not be used chronically)
- Discontinue if: Liver function tests increase >3× upper limit of normal
Critical Safety Considerations
The 5-day maximum duration is non-negotiable 1. Post-marketing surveillance demonstrates that adverse event rates, particularly GI bleeding, increase dramatically with:
Common pitfall: Using ketorolac prophylactically for anticipated pain. Ketorolac should only be administered for diagnosed injuries or conditions, not preventively 7.
Ketorolac provides opioid-sparing effects (approximately 36% reduction in opioid consumption) without necessarily reducing opioid-related side effects like nausea or vomiting 8. In cancer pain management, consider short-term ketorolac (15-30 mg IV every 6 hours for maximum 5 days) as an adjunct to opioids 3.
For acute migraine: 60 mg IM every 15-30 minutes (maximum 120 mg/day, treatment not to exceed 5 days) is effective 2.